As of 2024-12-12, the Relative Valuation of Citius Pharmaceuticals Inc (CTXR) is (116.70) USD. This relative valuation is based on P/E multiples. With the latest stock price at 3.06 USD, the upside of Citius Pharmaceuticals Inc based on Relative Valuation is -3913.8%.
The range of the Relative Valuation is (73.84) - (117.15) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 14.8x - 23.6x | 22.2x |
| Forward P/E multiples | 14.9x - 25.2x | 24.9x |
| Fair Price | (73.84) - (117.15) | (116.70) |
| Upside | -2513.0% - -3928.4% | -3913.8% |
| Date | P/E |
| 2024-12-09 | -0.67 |
| 2024-12-06 | -0.71 |
| 2024-12-05 | -0.74 |
| 2024-12-04 | -0.73 |
| 2024-12-03 | -0.72 |
| 2024-12-02 | -0.65 |
| 2024-11-29 | -0.67 |
| 2024-11-27 | -0.73 |
| 2024-11-26 | -0.84 |
| 2024-11-25 | -0.67 |
| 2024-11-22 | -0.68 |
| 2024-11-21 | -0.83 |
| 2024-11-20 | -0.86 |
| 2024-11-19 | -0.97 |
| 2024-11-18 | -1.13 |
| 2024-11-15 | -1.01 |
| 2024-11-14 | -1.66 |
| 2024-11-13 | -1.95 |
| 2024-11-12 | -2.43 |
| 2024-11-11 | -2.27 |
| 2024-11-08 | -2.08 |
| 2024-11-07 | -1.93 |
| 2024-11-06 | -1.75 |
| 2024-11-05 | -1.76 |
| 2024-11-04 | -1.76 |
| 2024-11-01 | -1.81 |
| 2024-10-31 | -1.88 |
| 2024-10-30 | -2.04 |
| 2024-10-29 | -1.97 |
| 2024-10-28 | -1.87 |
| 2024-10-25 | -1.84 |
| 2024-10-24 | -1.75 |
| 2024-10-23 | -1.80 |
| 2024-10-22 | -1.86 |
| 2024-10-21 | -1.94 |
| 2024-10-18 | -1.97 |
| 2024-10-17 | -2.07 |
| 2024-10-16 | -2.08 |
| 2024-10-15 | -1.89 |
| 2024-10-14 | -1.79 |
| 2024-10-11 | -1.85 |
| 2024-10-10 | -2.02 |
| 2024-10-09 | -1.98 |
| 2024-10-08 | -1.96 |
| 2024-10-07 | -1.99 |
| 2024-10-04 | -2.19 |
| 2024-10-03 | -2.25 |
| 2024-10-02 | -2.37 |
| 2024-10-01 | -2.36 |
| 2024-09-30 | -2.53 |